Fig. 3: Summary of antitumoral activity. | Nature Communications

Fig. 3: Summary of antitumoral activity.

From: BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Fig. 3

Source data are provided as a source data file. aConfirmed best response is presented for part C, defined as a consecutive response of the same or better that is at least 4 weeks apart, regardless of tumor type. bORR = CR + PR. cCBR = CR + PR + SD ≥4 months. CBR clinical benefit rate, CR complete response, DLBCL diffuse large B-cell lymphoma, ORR objective response rate, PR partial response, R/R relapsed/refractory, SD stable disease.

Back to article page